The wider risks in SoftBank’s US tech bet | 软银的豪赌 - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
FT英语电台

The wider risks in SoftBank’s US tech bet
软银的豪赌

The Japanese group’s options trade highlights the dangers of the market rally
这家日本巨头的期权交易凸显了市场反弹中蕴含的危险。
00:00

There are few business people who profess to have a plan for the next three years, let alone the next 300. Masayoshi Son, the Japanese entrepreneur behind SoftBank, wants his company to last that long, a goal that is meant to underpin the investments made by his $100bn Vision Fund. So the unmasking of SoftBank as the mystery “whale” whose options trading appears to have helped drive US technology stocks to record highs is a surprise — this type of trading appears at odds with the self-professed strategic nature of SoftBank’s investments. The revelation has, rightly, fuelled concerns that far from acting like a visionary technology investor, the group is behaving like a hedge fund. 

Whatever the exact details of SoftBank’s equity derivatives trade, the key question is whether the wider market cares. The answer is yes. Aside from the general curiosity — and sometimes mockery — that SoftBank attracts in the industry, investors and regulators should be alert to the consequences of one large, determined investor being able — at least in part — to influence the world’s largest, most liquid and most scrutinised stock market. 

Even before the identification of SoftBank, there were concerns that the US market was defying fundamentals, and that the one-sided rally in US technology stocks was unsustainable. Trading volumes on Nasdaq, where most of the big tech stocks are listed, are double what they were before the pandemic. Monetary stimulus by central banks in response to the pandemic have helped to propel equity markets higher. The retail trading boom, as day traders have turned to online trading platforms such as Robinhood, has also driven much of the activity, both in equities and derivatives. 

This surge of activity in the options markets is what makes some investors nervous. Financial institutions, advisers and regulators should be alert to the dangers of unsophisticated investors putting their money — or, even worse, borrowed money — to invest in higher-risk trades such as derivatives. In the event of a downturn, there is a possibility that some investors will lose their shirts, leading to real economic pain just as the downturn caused by the coronavirus pandemic bites.

In the case of SoftBank, its heavy bet on derivatives has done little to damp fears that the group has lost its strategic focus — even if it had already announced it would be setting up an asset management unit for public investments. It bears remembering that Japan’s corporate history is peppered with examples of companies and retail investors betting heavily on derivatives and getting burnt.

Many companies’ problems also often start when they have an excess of funds to deploy; the ill-fated foray of Germany’s Landesbanken into US subprime mortgages was triggered, in part, by a search for ways to invest a cash surplus. In the case of SoftBank, its recent tech investments were partly funded by cash from its $41bn asset disposal programme.

Some investors are already fearful of a market crash. Coronavirus looked like it had decisively ended the American equity market’s record bull run; its Lazarus-like revival in the past few months has only heightened the air of unreality. Previous market tumbles have normally had a tipping point, however small relative to the correction that followed. The recent drop in the valuations of tech stocks may have been enough to take some of the heat out of the market for now but a concern must be that SoftBank could be the snowflake that starts the avalanche.  

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

法律AI初创公司为律师开辟的另类职业路径

AI热潮正在为初级和资深律师开辟一条另类的职业路径:加入法律科技初创公司工作,且往往还能获得股权。

苹果、伯克希尔与耐心的美德

这两家公司等待绝佳机遇的耐心策略曾经奏效,但如今却愈发困难。

沃什应该倾听美联储的反对声音

在连续供应冲击下持续美联储宽松政策,是一种无视疫情教训的高风险做法。

Lex专栏:诺和诺德再迎问鼎减重药霸主地位的机会

减重药的第二波竞争已然打响,礼来和诺和诺德都已推出口服版本,而这一次,优势或许在诺和诺德这边。

FT社评:美国欠欧洲盟友一份防务路线图

美国的报复性削减开支无法实现合理的北约责任分担。

欧洲能否开发出欧洲版的“战斧”?

欧洲眼下推进的项目至少还要十年才能落地,但短期内并非没有权宜之计。
设置字号×
最小
较小
默认
较大
最大
分享×